PMID- 10214863
OWN - NLM
STAT- MEDLINE
DCOM- 19990510
LR  - 20190915
IS  - 0887-6924 (Print)
IS  - 0887-6924 (Linking)
VI  - 13
IP  - 4
DP  - 1999 Apr
TI  - Quantitation of minimal residual disease in acute myelogenous leukemia and 
      myelodysplastic syndromes in complete remission by molecular cytogenetics of 
      progenitor cells.
PG  - 568-77
AB  - Detection of karyotypic clonal abnormalities are prognostically useful in 
      patients with acute myelogenous leukemia (AML) and myelodysplastic syndromes 
      (MDS), but cytogenetic methods are not sensitive enough to detect low numbers of 
      residual leukemic cells in patients who have achieved complete remission (CR). 
      Fluorescence in situ hybridization (FISH) and fluorescence activated cell sorting 
      (FACS) were used to investigate the frequency and presence of minimal residual 
      disease (MRD) in AML and MDS patients (n = 28) with monosomy of chromosomes 7, 17 
      and 18 and trisomy of chromosomes 6, 8, 9 and 10 in CR. MRD was detected in all 
      patients with monosomy 7 (n = 10) and followed by relapse in eight patients after 
      4.8 +/- 3.1 months. In contrast, persistent leukemic cells occurred in 11/12 
      patients with trisomy 8, but only three of them relapsed after 7.7 +/- 4.0 
      months. Cox regression analysis showed that cytogenetic class and levels of 
      clonal cells at CR were related to time to relapse (P = 0.001). The level of MRD 
      identified patients at high and low risk of relapse. High absolute levels of 
      proliferating residual leukemic cells correlated with monosomy 7 and high risk of 
      relapse.
FAU - Engel, H
AU  - Engel H
AD  - Department of Hematology, The University of Texas MD Anderson Cancer Center, 
      Houston, USA.
FAU - Drach, J
AU  - Drach J
FAU - Keyhani, A
AU  - Keyhani A
FAU - Jiang, S
AU  - Jiang S
FAU - Van, N T
AU  - Van NT
FAU - Kimmel, M
AU  - Kimmel M
FAU - Sanchez-Williams, G
AU  - Sanchez-Williams G
FAU - Goodacre, A
AU  - Goodacre A
FAU - Andreeff, M
AU  - Andreeff M
LA  - eng
GR  - CA16672/CA/NCI NIH HHS/United States
GR  - CA55164/CA/NCI NIH HHS/United States
GR  - CA57639/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - England
TA  - Leukemia
JT  - Leukemia
JID - 8704895
RN  - 0 (Antigens, Differentiation)
RN  - 0 (Antigens, Neoplasm)
SB  - IM
MH  - Acute Disease
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anemia, Refractory, with Excess of Blasts/diagnosis/genetics/pathology
MH  - Antigens, Differentiation/analysis
MH  - Antigens, Neoplasm/analysis
MH  - Cell Division
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human, Pair 7
MH  - Clone Cells/chemistry/ultrastructure
MH  - Disease Progression
MH  - Disease-Free Survival
MH  - Female
MH  - Flow Cytometry
MH  - Hematopoietic Stem Cells/chemistry/*ultrastructure
MH  - Humans
MH  - Immunophenotyping
MH  - In Situ Hybridization, Fluorescence
MH  - Karyotyping
MH  - Leukemia, Myeloid/classification/diagnosis/genetics/*pathology
MH  - Life Tables
MH  - Male
MH  - Middle Aged
MH  - Monosomy
MH  - Myelodysplastic Syndromes/classification/diagnosis/genetics/*pathology
MH  - Neoplasm, Residual
MH  - Neoplastic Stem Cells/chemistry/*ultrastructure
MH  - Proportional Hazards Models
MH  - Recurrence
EDAT- 1999/04/24 00:00
MHDA- 1999/04/24 00:01
CRDT- 1999/04/24 00:00
PHST- 1999/04/24 00:00 [pubmed]
PHST- 1999/04/24 00:01 [medline]
PHST- 1999/04/24 00:00 [entrez]
AID - 10.1038/sj.leu.2401359 [doi]
PST - ppublish
SO  - Leukemia. 1999 Apr;13(4):568-77. doi: 10.1038/sj.leu.2401359.